Diabetes patients ditch GLP-1s early

The study, presented at the recent Australian Diabetes Society meeting, showed that from a cohort of 6186 patients with type 2 diabetes, of the 442 who had ever received a GLP-1 agonist, 52% of patients had stopped the drug a mean 7.6 months after initiation.

In 38% of cases, the reason for ceasing treatment was lack of efficacy, and in 20% of cases it was because of adverse reactions.

Study author Dr David Hoffman, a private endocrinologist in